Polycystic Kidney Disease Drugs Companies

  • Report ID: 4323
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Companies Dominating the Polycystic Kidney Disease Drugs Landscape

    • Otsuka Pharmaceutical Co., Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Exelixis, Inc.
    • XORTX Therapeutics, Inc.
    • AstraZeneca PLC
    • Manros Therapeutics
    • Regulus Therapeutics Inc.
    • Reata Pharmaceuticals, Inc.
    • Pano Therapeutics, Inc.
    • Taro Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc.

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of polycystic kidney disease drugs is evaluated at USD 571.38 million.

The polycystic kidney disease drugs market size was over USD 513.94 million in 2024 and is poised to exceed USD 1.21 billion by 2037, witnessing over 6.8% CAGR during the forecast period i.e., between 2025-2037. The surge in the incidence of autosomal dominant polycystic kidney diseases (ADPKD), and growing initiatives to raise awareness about PKDs will boost the market growth.

North America industry is predicted to dominate majority revenue share by 2037, attributed to rise in per capita income, along with rising awareness of the early diagnosis of chronic kidney diseases as of the advancement in the medical array in the region.

The major players in the market are Otsuka Pharmaceutical Co., Ltd., Exelixis, Inc., XORTX Therapeutics, Inc., AstraZeneca PLC, Manros Therapeutics, Regulus Therapeutics Inc., Reata Pharmaceuticals, Inc., Pano Therapeutics, Inc., Taro Pharmaceutical Industries Ltd., GlaxoSmithKline plc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos